Xeris Pharmaceuticals (NASDAQ:XERS) Rating Reiterated by Mizuho

Mizuho reissued their buy rating on shares of Xeris Pharmaceuticals (NASDAQ:XERS) in a report published on Tuesday, AnalystRatings.com reports. Mizuho currently has a $22.00 price objective on the stock.

A number of other brokerages have also recently issued reports on XERS. ValuEngine cut shares of Xeris Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, September 30th. Zacks Investment Research raised shares of Xeris Pharmaceuticals from a sell rating to a hold rating in a research note on Saturday, November 16th.

Shares of Xeris Pharmaceuticals stock traded down $0.19 during midday trading on Tuesday, reaching $5.85. The company had a trading volume of 2,137 shares, compared to its average volume of 290,677. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 1.33. The company has a market capitalization of $166.02 million, a price-to-earnings ratio of -1.31 and a beta of -0.48. The stock has a fifty day simple moving average of $7.20 and a 200 day simple moving average of $9.29. Xeris Pharmaceuticals has a 1-year low of $5.30 and a 1-year high of $15.82.

Xeris Pharmaceuticals (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.01. The business had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.20 million. Xeris Pharmaceuticals had a negative net margin of 6,697.33% and a negative return on equity of 150.08%. Sell-side analysts expect that Xeris Pharmaceuticals will post -4.79 earnings per share for the current year.

In other Xeris Pharmaceuticals news, insider Steven Prestrelski sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $5.50, for a total value of $55,000.00. Following the transaction, the insider now directly owns 421,824 shares of the company’s stock, valued at $2,320,032. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Paul R. Edick acquired 17,935 shares of Xeris Pharmaceuticals stock in a transaction on Monday, November 25th. The stock was acquired at an average cost of $8.55 per share, for a total transaction of $153,344.25. Following the completion of the purchase, the insider now owns 172,935 shares of the company’s stock, valued at approximately $1,478,594.25. The disclosure for this purchase can be found here. 7.43% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in XERS. Marshall Wace LLP bought a new position in shares of Xeris Pharmaceuticals during the first quarter worth $245,000. Marshall Wace North America L.P. bought a new position in shares of Xeris Pharmaceuticals during the first quarter worth $71,000. FMR LLC boosted its position in shares of Xeris Pharmaceuticals by 29.9% during the first quarter. FMR LLC now owns 2,963,018 shares of the company’s stock worth $29,749,000 after purchasing an additional 682,050 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Xeris Pharmaceuticals by 241.5% during the second quarter. Wells Fargo & Company MN now owns 41,973 shares of the company’s stock worth $480,000 after purchasing an additional 29,682 shares in the last quarter. Finally, Bank of Montreal Can bought a new position in shares of Xeris Pharmaceuticals during the second quarter worth $26,000. 66.37% of the stock is currently owned by institutional investors.

Xeris Pharmaceuticals Company Profile

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

See Also: Closed-End Mutual Funds

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit